Etiology and pathogenesis of adverse drug reactions

Chemical Immunology and Allergy

Volumn 97, Issue , 2012, Pages 32-46

  Hausmann, O ^a   Schnyder, B ^a   Pichler, W J ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CODEINE; CONTRAST MEDIUM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMMUNOGLOBULIN E; MORPHINE; NEUROMUSCULAR BLOCKING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ANGIONEUROTIC EDEMA; ANTIGEN PRESENTING CELL; ARTICLE; COUGHING; DRUG CROSS REACTIVITY; DRUG HYPERSENSITIVITY; HEREDITY; HUMAN; IMMUNE COMPLEX DEPOSITION; IMMUNOCYTOTOXICITY; MAST CELL DEGRANULATION; PATHOGENESIS; PRIORITY JOURNAL; RASH; SENSITIZATION; SKIN ALLERGY; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANTIGEN-ANTIBODY COMPLEX; BASOPHILS; CYTOKINES; DERMATITIS, CONTACT; DRUG TOXICITY; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNOGLOBULIN E; INFLAMMATION MEDIATORS; MAST CELLS; PHARMACEUTICAL PREPARATIONS; T-LYMPHOCYTES;

EID: 84861432695     PISSN: 16602242     EISSN: 16622898     Source Type: Book Series    
DOI: 10.1159/000335614     Document Type: Article

References (53)

1. International drug monitoring: the role of national centres. Report of a WHO meeting. World Health Organ Tech Rep Ser 1972;498:1-25.
2. Edwards IR, Aronson JK: Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000; 356:1255-1259.
3. Meyboom RH, Lindquist M, Egberts AC: An ABC of drug-related problems. Drug Saf 2000;22:415-423.
4. Aronson JK, Ferner RE: Joining the DoTS: new approach to classifying adverse drug reactions. BMJ 2003;327:1222-1225.
5. Nebeker JR, Barach P, Samore MH: Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting. Ann Intern Med 2004;140:795-801.
6. Rawlins MD, Thompson JW: Pathogenesis of adverse drug reactions. In: Davies DM (ed) Textbook of adverse drug reactions. Oxford: Oxford University Press, 1977, pp 10-17.
7. Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, et al: Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 2004;113:832-836.
8. Abbas AK, Lichtman AH: Cellular and Molecular Immunology, 6th updated ed. Philadelphia: Saunders, 2009.
9. Desgeorges A, Gabay C, Silacci P, Novick D, Roux-Lombard P, Grau G, et al: Concentrations and origins of soluble interleukin 6 receptor-alpha in serum and synovial fluid. J Rheumatol 1997;24:1510-1516.
10. Vasquez EM, Fabrega AJ, Pollak R: OKT3-induced cytokine-release syndrome: occurrence beyond the second dose and association with rejection severity. Transplant Proc 1995;27:873-874.
11. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, et al: Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006;355: 1018-1028.
12. Faich GA: Adverse-drug-reaction monitoring. N Engl J Med 1986;314:1589-1592.
13. Szczeklik A, Stevenson DD: Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management. J Allergy Clin Immunol 2003;111: 913-921, quiz 922.
14. Cowburn AS, Sladek K, Soja J, Adamek L, Nizankowska E, Szczeklik A, et al: Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest 1998;101:834-846.
15. Israili ZH, Hall WD: Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med 1992;117: 234-242.
16. Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A: Plasma bradykinin in angio-oedema. Lancet 1998;351:1693-1697.
17. Adam A, Cugno M, Molinaro G, Perez M, Lepage Y, Agostoni A: Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors. Lancet 2002;359:2088-2089.
18. Lefebvre J, Murphey LJ, Hartert TV, Jiao Shan R, Simmons WH, Brown NJ: Dipeptidyl peptidase IV activity in patients with ACE-inhibitor-associated angioedema. Hypertension 2002;39:460-464.
19. Casale TB, Bowman S, Kaliner M: Induction of human cutaneous mast cell degranulation by opiates and endogenous opioid peptides: evidence for opiate and nonopiate receptor participation. J Allergy Clin Immunol 1984;73:775-781.
20. Blunk JA, Schmelz M, Zeck S, Skov P, Likar R, Koppert W: Opioid-induced mast cell activation and vascular responses is not mediated by mu-opioid receptors: an in vivo microdialysis study in human skin. Anesth Analg 2004;98:364-370.
21. Tharp MD, Kagey-Sobotka A, Fox CC, Marone G, Lichtenstein LM, Sullivan TJ: Functional heterogeneity of human mast cells from different anatomic sites: in vitro responses to morphine sulfate. J Allergy Clin Immunol 1987;79:646-653.
22. Lagunoff D, Martin TW, Read G: Agents that release histamine from mast cells. Annu Rev Pharmacol Toxicol 1983;23:331-351.
23. Brockow K, Romano A, Aberer W, Bircher AJ, Barbaud A, Bonadonna P, et al: Skin testing in patients with hypersensitivity reactions to iodinated contrast media -a European multicenter study. Allergy 2009;64:234-241.
24. Ebo DG, Bridts CH, Hagendorens MM, Mertens CH, De Clerck LS, Stevens WJ: Flow-assisted diagnostic management of anaphylaxis from rocuronium bromide. Allergy 2006;61:935-939.
25. Mertes PM, Laxenaire MC: Allergic reactions occurring during anaesthesia. Eur J Anaesthesiol 2002;19: 240-262.
26. Riley RJ, Leeder JS: In vitro analysis of metabolic predisposition to drug hypersensitivity reactions. Clin Exp Immunol 1995;99:1-6.
27. Stavnezer J, Amemiya CT: Evolution of isotype switching. Semin Immunol 2004;16:257-275.
28. Gerber BO, Pichler WJ: Cellular mechanisms of T cell mediated drug hypersensitivity. Curr Opin Immunol 2004;16:732-737.
29. Aster RH: Drug-induced immune cytopenias. Toxicology 2005;209:149-153.
30. Reese JA, Li X, Hauben M, Aster RH, Bougie DW, Curtis BR, et al: Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods. Blood 116:2127-2133.
31. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, et al: Heparin-induced thrombocytopenia in patients treated with low-molecularweight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-1335.
32. Roychowdhury S, Svensson CK: Mechanisms of drug-induced delayed-type hypersensitivity reactions in the skin. AAPS J 2005;7:E834-E846.
33. Pichler WJ: Delayed drug hypersensitivity reactions. Ann Intern Med 2003;139:683-693.
34. Gorbachev AV, Fairchild RL: Induction and regulation of T-cell priming for contact hypersensitivity. Crit Rev Immunol 2001;21:451-472.
35. Saint-Mezard P, Krasteva M, Chavagnac C, Bosset S, Akiba H, Kehren J, et al: Afferent and efferent phases of allergic contact dermatitis (ACD) can be induced after a single skin contact with haptens: evidence using a mouse model of primary ACD. J Invest Dermatol 2003;120:641-647.
36. Budinger L, Hertl M: Immunologic mechanisms in hypersensitivity reactions to metal ions: an overview. Allergy 2000;55:108-115.
37. Naisbitt DJ, Gordon SF, Pirmohamed M, Park BK: Immunological principles of adverse drug reactions: the initiation and propagation of immune responses elicited by drug treatment. Drug Saf 2000;23: 483-507.
38. Jensen CS, Lisby S, Larsen JK, Veien NK, Menne T: Characterization of lymphocyte subpopulations and cytokine profiles in peripheral blood of nickel-sensitive individuals with systemic contact dermatitis after oral nickel exposure. Contact Dermatitis 2004; 50:31-38.
39. Ebert LM, Schaerli P, Moser B: Chemokinemediated control of T cell traffic in lymphoid and peripheral tissues. Mol Immunol 2005;42:799-809.
40. Mora JR, von Andrian UH: T-cell homing specificity and plasticity: new concepts and future challenges. Trends Immunol 2006;27:235-243.
41. Posadas SJ, Pichler WJ: Delayed drug hypersensitivity reactions -new concepts. Clin Exp Allergy 2007; 37:989-999.
42. Schmid DA, Depta JP, Luthi M, Pichler WJ: Transfection of drug-specific T-cell receptors into hybridoma cells: tools to monitor drug interaction with T-cell receptors and evaluate cross-reactivity to related compounds. Mol Pharmacol 2006;70:356-365.
43. Schnyder B, Mauri-Hellweg D, Zanni M, Bettens F, Pichler WJ: Direct, MHC-dependent presentation of the drug sulfamethoxazole to human alphabeta T cell clones. J Clin Invest 1997;100:136-141.
44. Zanni MP, von Greyerz S, Schnyder B, Brander KA, Frutig K, Hari Y, et al: HLA-restricted, processingand metabolism-independent pathway of drug recognition by human alpha beta T lymphocytes. J Clin Invest 1998;102:1591-1598.
45. Clark RA, Chong B, Mirchandani N, Brinster NK, Yamanaka K, Dowgiert RK, et al: The vast majority of CLA+ T cells are resident in normal skin. J Immunol 2006;176:4431-4439.
46. Schaerli P, Moser B: Chemokines: control of primary and memory T-cell traffic. Immunol Res 2005; 31:57-74.
47. Croft M: Activation of naive, memory and effector T cells. Curr Opin Immunol 1994;6:431-437.
48. Rogers PR, Dubey C, Swain SL: Qualitative changes accompany memory T cell generation: faster, more effective responses at lower doses of antigen. J Immunol 2000;164:2338-2346.
49. Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, et al: Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3- galactose. N Engl J Med 2008;358:1109-1117.
50. Harboe T, Johansson SG, Florvaag E, Oman H: Pholcodine exposure raises serum IgE in patients with previous anaphylaxis to neuromuscular blocking agents. Allergy 2007;62:1445-1450.
51. Kvedariene V, Martins P, Rouanet L, Demoly P: Diagnosis of iodinated contrast media hypersensitivity: results of a 6-year period. Clin Exp Allergy 2006;36:1072-1077.
52. Descamps V, Valance A, Edlinger C, Fillet AM, Grossin M, Lebrun-Vignes B, et al: Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms. Arch Dermatol 2001;137:301-304.
53. Chung WH, Hung SI, Chen YT: Human leukocyte antigens and drug hypersensitivity. Curr Opin Allergy Clin Immunol 2007;7:317-323.